Medicine
Potassium Phosphates 11800 mg/11200 mg per 50 mL injection
Potassium Phosphates 11800 mg/11200 mg per 50 mL injection is a prescription medicine containing Dibasic and Monobasic for intravenous use, marketed by Fresenius Kabi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F). For storage of admixed solution see…
Key facts
- Active ingredient (INN)
- Dibasic and Monobasic
- Brand
- Potassium Phosphates
- Strength
- 11800 mg/11200 mg per 50 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 25 vials of 50 mL
- Marketing authorisation holder
- Fresenius Kabi
- Manufacturer
- Fresenius Kabi
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F). For storage of admixed solution see Dosage and Administration 2.1, 2.3.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 February 2020
- Identifiers
- RxCUI 1928567, 1928569, 2667657DailyMed set ID 475f5cd7-45bd-412a-b419-9962585d6cdaNDC 65219-056Application NDA212832
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 vial in 1 tray / 50 mL in 1 vial | 65219-056-29 | Fresenius Kabi | 10 February 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Dibasic and Monobasic 11800 mg/11200 mg per 50 mL injection.
Other strengths and forms of Dibasic and Monobasic
Clinical summary
Dibasic and Monobasic is a fixed-dose combination of an osmotic laxative and a potassium salt indicated as a source of phosphorus, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Dibasic and Monobasic for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Dibasic and MonobasicFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Potassium Phosphates prescribing information (Civica) · U.S. National Library of Medicine, DailyMed
Need Potassium Phosphates 11800 mg/11200 mg per 50 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.